Floatz logo

cd19-ucart

Acute Lymphoblastic Leukemia, Adult B-Cell

The General Hospital of Western Theater CommandCell therapyPhase 1Active
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
39/ 100
Competitive Position
89/ 100

Competitive context

23 Active assets in the Acute Lymphoblastic Leukemia, Adult B-Cell cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
SWOG Cancer Research Network
Phase 3BBB
PEGASPARGASE
National Cancer Institute (NCI)
Phase 3BBB
DEXAMETHASONE
Mayo Clinic
Phase 3BBB
Cyclophosphamide
The First Affiliated Hospital of Soochow University
Phase 3BBB
METHOTREXATE
Massachusetts General Hospital
Phase 3BBB

View all 50 →

Same molecule, other indications

cd19-ucart is also rated in:

B-Cell Acute Lymphoblastic Leukemia, AdultDormant
BBB
Indicative ·
72 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
BB
Indicative ·
71 / 100
View asset →
B-cell acute lymphoblastic leukemiaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →